Plasma amyloid beta, neurofilament light chain, and total tau in the Systolic Blood Pressure Intervention Trial (SPRINT).
Plasma amyloid beta, neurofilament light chain, and total tau in the Systolic Blood Pressure Intervention Trial (SPRINT).
复制标题
DOI：
10.1002/alz.12496
复制
发表时间：
2022-08
影响因子：
14
通讯作者：
Williamson, Jeff D.
中科院分区：
文献类型：
--
作者：
Pajewski, Nicholas M.;Elahi, Fanny M.;Tamura, Manjula Kurella;Hinman, Jason D.;Nasrallah, Ilya M.;Ix, Joachim H.;Miller, Lindsay M.;Launer, Lenore J.;Wright, Clinton B.;Supiano, Mark A.;Lerner, Alan J.;Sudduth, Tiffany L.;Killeen, Anthony A.;Cheung, Alfred K.;Reboussin, David M.;Wilcock, Donna M.;Williamson, Jeff D.
降低血压（BP）可降低认知障碍和脑白色病变进展的风险。尚不清楚高血压控制是否也影响与阿尔茨海默病和非疾病特异性神经变性相关的血浆生物标志物。我们研究了强化（<120 mm Hg）与标准（<140 mm Hg）血压控制对来自Syphilis血压干预试验（N=517）的一个亚组参与者血浆Aβ40和Aβ42、总tau蛋白和神经丝轻链（NfL）纵向变化的影响。在3.8年期间，Aβ40、Aβ42、Aβ42 / Aβ40或总tau无显著组间差异。与标准治疗相比，强化治疗与NfL的较大增加相关。调整肾功能，而不是血压，减弱强化治疗和NfL之间的关联。强化BP治疗与NfL的变化相关，NfL与强化治疗相关的肾功能变化相关。clinicaltrials.gov标识符：NCT 01206062
Blood pressure (BP) lowering reduces the risk for cognitive impairment and the progression of cerebral white matter lesions. It is unclear whether hypertension control also influences plasma biomarkers related to Alzheimer’s disease and non-disease-specific neurodegeneration. We examined the effect of intensive (<120 mm Hg) vs standard (<140 mm Hg) BP control on longitudinal changes in plasma Aβ40 and Aβ42, total tau, and neurofilament light chain (NfL) in a subgroup of participants from the Systolic Blood Pressure Intervention Trial (N=517). Over 3.8 years, there were no significant between-group differences for Aβ40, Aβ42, Aβ42 / Aβ40, or total tau. Intensive treatment was associated with larger increases in NfL compared to standard treatment. Adjusting for kidney function, but not BP, attenuated the association between intensive treatment and NfL. Intensive BP treatment was associated with changes in NfL, which were correlated with changes in kidney function associated with intensive treatment. clinicaltrials.gov Identifier: NCT01206062
登录
查看更多内容
DOI：
10.1001/jama.2017.3090
发表时间：
2017-04-11
期刊：
JAMA
影响因子：
--
作者：
Gottesman RF;Schneider AL;Zhou Y;Coresh J;Green E;Gupta N;Knopman DS;Mintz A;Rahmim A;Sharrett AR;Wagenknecht LE;Wong DF;Mosley TH
通讯作者：
Mosley TH
影响因子：
9.9
作者：
Mattsson N;Zetterberg H;Janelidze S;Insel PS;Andreasson U;Stomrud E;Palmqvist S;Baker D;Tan Hehir CA;Jeromin A;Hanlon D;Song L;Shaw LM;Trojanowski JQ;Weiner MW;Hansson O;Blennow K;ADNI Investigators
通讯作者：
ADNI Investigators
DOI：
10.1177/1740774514537404
发表时间：
2014-10
期刊：
Clinical trials (London, England)
影响因子：
--
作者：
Ambrosius WT;Sink KM;Foy CG;Berlowitz DR;Cheung AK;Cushman WC;Fine LJ;Goff DC Jr;Johnson KC;Killeen AA;Lewis CE;Oparil S;Reboussin DM;Rocco MV;Snyder JK;Williamson JD;Wright JT Jr;Whelton PK;SPRINT Study Research Group
通讯作者：
SPRINT Study Research Group
影响因子：
8.3
作者：
Liao, DP;Cooper, L;Tyroler, HA
通讯作者：
Tyroler, HA
影响因子：
1.9
作者：
Liu Q;Li C;Wanga V;Shepherd BE
通讯作者：
Shepherd BE